SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M. Shah, A. Shankar, I. Gee, K. Nash, M. Hoare, P. Gibbs, S. Davies, G. J. M. Alexander, A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients, Alimentary Pharmacology & Therapeutics, 2015, 41, 4
  2. 2
    Liangfeng Gu, Wei Jin, Liandi Kan, Xia Wang, Chunlei Shan, Hui Fan, A Retrospective Study to Compare the use of Tacrolimus and Cyclosporine in Combination with Adriamycin in Post-Transplant Liver Cancer Patients, Cell Biochemistry and Biophysics, 2015, 71, 2, 565

    CrossRef

  3. 3
    Kuo-Hsin Chen, Chih-Yuan Lee, Fe-Lin Lin Wu, Ching-Yao Yang, Chi-Chuan Yeh, Rey-Heng Hu, Meng-Kun Tsai, De novo cancer avoidance after renal transplantation: A case–control study on low-dose sirolimus combined with a calcineurin inhibitor, Journal of the Formosan Medical Association, 2015, 114, 6, 526

    CrossRef

  4. 4
    Christophe Duvoux, Christian Toso, mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?, Transplantation Reviews, 2015, 29, 3, 168

    CrossRef

  5. 5
    Greg J. McKenna, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  6. 6
    Michael A. Zimmerman, Nicholas Onaca, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  7. 7
    Richard Ruiz, Allan D. Kirk, Transplantation of the Liver, 2015,

    CrossRef

  8. 8
    Nicholas Onaca, Marvin J. Stone, James M. Fulmer, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  9. 9
    Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, Dimitrios Giakoustidis, George Imvrios, Olga Giouleme, Vasilios Papanikolaou, Evangelos Akriviadis, Themistoklis Vasiliadis, Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience, Hepatology International, 2014, 8, 1, 137

    CrossRef

  10. 10
    A.O. Ferreiro, M.A. Vazquez-Millán, F.S. López, M.G. Gutiérrez, S.P. Diaz, M.J.L. Patiño, Everolimus-Based Immunosuppression in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Liver Transplantation: A Case Series, Transplantation Proceedings, 2014, 46, 10, 3496

    CrossRef

  11. 11
    Manuel Rodríguez-Perálvarez, Manuel De la Mata, Andrew K. Burroughs, Liver transplantation, Current Opinion in Organ Transplantation, 2014, 19, 3, 253

    CrossRef

  12. 12
    Renumathy Dhanasekaran, Julie K. Heimbach, Liver Transplantation for Hepatocellular Carcinoma, Current Transplantation Reports, 2014, 1, 4, 215

    CrossRef

  13. 13
    Evangelos Cholongitas, Chrysanthi Mamou, Kryssia I. Rodríguez-Castro, Patrizia Burra, Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review, Transplant International, 2014, 27, 10
  14. 14
    C.M. Sommer, U. Stampfl, H.U. Kauczor, P.L. Pereira, Nationale S3-Leitlinie hepatozelluläres Karzinom, Der Radiologe, 2014, 54, 7, 642

    CrossRef

  15. 15
    Kan Chen, Kwan Man, Herold J. Metselaar, Harry L. A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan, Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation, Liver Transplantation, 2014, 20, 3
  16. 16
    Young-Nam Roh, Choon Hyuck David Kwon, Sanghyun Song, Milljae Shin, Jong Man Kim, Sungjoo Kim, Jae-Won Joh, Suk-Koo Lee, The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation, Clinical Transplantation, 2014, 28, 1
  17. 17
    Goran B. Klintmalm, Björn Nashan, The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence, Journal of Transplantation, 2014, 2014, 1

    CrossRef

  18. 18
    Cong Wu, Yi Zhang, Yingming Jiang, Quanxing Wang, Yao Long, Chunmei Wang, Xuetao Cao, Guoyou Chen, Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells, Cellular and Molecular Immunology, 2013, 10, 5, 393

    CrossRef

  19. 19
    Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial, Liver Transplantation, 2013, 19, 7
  20. You have free access to this content20
    K. V. Menon, A. R. Hakeem, N. D. Heaton, Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2013, 37, 4
  21. 21
    Martin-Walter Welker, Wolf-Otto Bechstein, Stefan Zeuzem, Joerg Trojan, Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge, Transplant International, 2013, 26, 2
  22. 22
    Goran Klintmalm, Cliona O'Farrelly, Taking the rap: Multiple effects of blocking mammalian target of rapamycin, Hepatology, 2013, 57, 1
  23. 23
    Angel Rubín, Marina Berenguer, Trasplante hepático: inmunosupresión personalizada en pacientes con hepatitis C y carcinoma hepatocelular, Gastroenterología y Hepatología, 2013, 36, 1, 48

    CrossRef

  24. 24
    Peter T. W. Kim, Nicholas Onaca, Srinath Chinnakotla, Gary L. Davis, Linda W. Jennings, Greg J. McKenna, Richard M. Ruiz, Marlon F. Levy, Robert Goldstein, Goran B. Klintmalm, Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation, Clinical Transplantation, 2013, 27, 2
  25. 25
    Emmanuel Melloul, Mickael Lesurtel, Brian I. Carr, Pierre-Alain Clavien, Developments in Liver Transplantation for Hepatocellular Carcinoma, Seminars in Oncology, 2012, 39, 4, 510

    CrossRef

  26. 26
    G. Felga, A.S. Evangelista, P.R. Salvalaggio, L.A. Curvelo, B. Della Guardia, M.D. Almeida, R.C. Afonso, B.H. Ferraz-Neto, Hepatocellular Carcinoma Recurrence Among Liver Transplant Recipients Within the Milan Criteria, Transplantation Proceedings, 2012, 44, 8, 2459

    CrossRef

  27. 27
    Katharina Staufer, Lutz Fischer, Barbara Seegers, Eik Vettorazzi, Bjoern Nashan, Martina Sterneck, High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation, Transplant International, 2012, 25, 11
  28. 28
    Ali Zarrinpar, Ronald W Busuttil, Immunomodulating options for liver transplant patients, Expert Review of Clinical Immunology, 2012, 8, 6, 565

    CrossRef

  29. 29
    Rahul Kakodkar, A. S. Soin, Liver Transplantation for HCC: A Review, Indian Journal of Surgery, 2012, 74, 1, 100

    CrossRef

  30. 30
    Josep M. Campistol, Valentín Cuervas-Mons, Nicolás Manito, Luis Almenar, Manuel Arias, Fernando Casafont, Domingo del Castillo, María G. Crespo-Leiro, Juan F. Delgado, J. Ignacio Herrero, Paloma Jara, José M. Morales, Mercedes Navarro, Federico Oppenheimer, Martín Prieto, Luis A. Pulpón, Antoni Rimola, Antonio Román, Daniel Serón, Piedad Ussetti, New concepts and best practices for management of pre- and post-transplantation cancer, Transplantation Reviews, 2012, 26, 4, 261

    CrossRef

  31. 31
    Güçlü Kaan Beriat, Şefik Halit Akmansu, Cem Doğan, Eren Taştan, Ferda Topal, Bizden Sabuncuoğlu, Pimecrolimus kremin (%1) atopik dermatit tedavisindeki etkinliği, Medical Science Monitor, 2012, 18, 4, BR135

    CrossRef

  32. 32
    Pierre-Alain Clavien, Mickael Lesurtel, Patrick MM Bossuyt, Gregory J Gores, Bernard Langer, Arnaud Perrier, Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report, The Lancet Oncology, 2012, 13, 1, e11

    CrossRef

  33. 33
    Richard Ruiz, Goran B. Klintmalm, Renal-sparing regimens employing new agents, Current Opinion in Organ Transplantation, 2012, 17, 6, 619

    CrossRef

  34. 34
    Martin-Walter Welker, Jörg Trojan, Rezidiv des hepatozellulären Karzinoms nach orthotoper Lebertransplantation: Nachsorge und therapeutische Optionen, Viszeralmedizin, 2012, 28, 5, 338

    CrossRef

  35. 35
    Greg J. McKenna, James F. Trotter, Sirolimus – It doesn’t deserve its bad Rap(a), Journal of Hepatology, 2012, 56, 1, 285

    CrossRef

  36. 36
    Wenhua Liang, Dongping Wang, Xiaoting Ling, Andrew Allen Kao, Yuan Kong, Yushu Shang, Zhiyong Guo, Xiaoshun He, Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis, Liver Transplantation, 2012, 18, 1
  37. 37
    J. R. L. Maggs, A. R. Suddle, V. Aluvihare, M. A. Heneghan, Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2012, 35, 10
  38. 38
    Omar Massoud, Russell H. Wiesner, The use of Sirolimus should be restricted in liver transplantation, Journal of Hepatology, 2012, 56, 1, 288

    CrossRef

  39. 39
    Valentina Rosa Bertuzzo, Matteo Cescon, Matteo Ravaioli, Gian Luca Grazi, Giorgio Ercolani, Massimo Del Gaudio, Alessandro Cucchetti, Antonietta DʼErrico-Grigioni, Rita Golfieri, Antonio Daniele Pinna, Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers, Transplantation, 2011, 91, 11, 1279

    CrossRef

  40. 40
    Faouzi Saliba, Sébastien Dharancy, Richard Lorho, Filoména Conti, Sylvie Radenne, Martine Neau-Cransac, Monika Hurtova, Jean Hardwigsen, Yvon Calmus, Jérome Dumortier, Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis, Liver Transplantation, 2011, 17, 8
  41. 41
    Rudi Henriksen, Flemming Brandt Sørensen, Torben Falck Ørntoft, Karin Birkenkamp-Demtroder, Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium, Tumor Biology, 2011, 32, 4, 671

    CrossRef

  42. 42
    A.A. Schnitzbauer, P.E. Lamby, I. Mutzbauer, J. von Hassel, E.K. Geissler, H.J. Schlitt, Herausforderungen in der Organisation „investigator initiated trials“, Der Chirurg, 2011, 82, 3, 249

    CrossRef

  43. 43
    Hans J. Schlitt, Françoise Mornex, Abraham Shaked, James F. Trotter, Immunosuppression and hepatocellular carcinoma, Liver Transplantation, 2011, 17, S2
  44. 44
    Andreas A. Schnitzbauer, Hans J. Schlitt, Edward K. Geissler, Influence of Immunosuppressive Drugs on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Gap Between Basic Science and Clinical Evidence, Transplantation, 2011, 91, 11, 1173

    CrossRef

  45. 45
    Toshiyasu Kawahara, Sonal Asthana, Norman M. Kneteman, m-TOR inhibitors: What role in liver transplantation?, Journal of Hepatology, 2011, 55, 6, 1441

    CrossRef

  46. 46
    Josh Levitsky, Olaf Guckelberger, Meeting Report of the 16th Annual International Congress of the International Liver Transplantation Society, Liver Transplantation, 2011, 17, 1
  47. 47
    Shugo Mizuno, Takashi Hamada, Kaname Nakatani, Masashi Kishiwada, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Yuko Sakamoto, Junji Nishioka, Yuichi Muraki, Masahiro Okuda, Tsutomu Nobori, Shuji Isaji, Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype, Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 2
  48. 48
    Christine Wu, Ron Shapiro, Post-transplant malignancy: reducing the risk in kidney transplant recipients, Expert Opinion on Pharmacotherapy, 2011, 1

    CrossRef

  49. 49
    Nicholas N. Nissen, Vijay Menon, Catherine Bresee, Tram T. Tran, Alagappan Annamalai, Fred Poordad, Jeffrey H. Fair, Andrew S. Klein, Brendan Boland, Steven D. Colquhoun, Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient, HPB, 2011, 13, 9
  50. 50
    D.M. Harnois, Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation, Yearbook of Gastroenterology, 2010, 2010, 246

    CrossRef

  51. 51
    Christopher Soll, Pierre-Alain Clavien, Inhibition of mammalian target of rapamycin: The janus face of immunosuppression?, Hepatology, 2010, 51, 4
  52. 52
    Kwang-Woong Lee, Kyung-Suk Suh, Liver Transplantation for Advanced Hepatocellular Carcinoma, The Journal of the Korean Society for Transplantation, 2010, 24, 1, 4

    CrossRef

  53. 53
    Matteo Cescon, Matteo Ravaioli, Gian Luca Grazi, Giorgio Ercolani, Alessandro Cucchetti, Valentina Bertuzzo, Gaetano Vetrone, Massimo Del Gaudio, Marco Vivarelli, Antonietta D'Errico-Grigioni, Alessandro Dazzi, Paolo Di Gioia, Augusto Lauro, Antonio Daniele Pinna, Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma, Journal of Transplantation, 2010, 2010, 1

    CrossRef

  54. 54
    Russell H. Wiesner, Immunosuppression: The Global Picture,
  55. 55
    Abby B. Siegel, Vladimir Sheynzon, Benjamin Samstein, Uncommon Hepatobiliary Tumors,